Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Inclusion Criteria:

• CML Ph+ (assessed by cytogenetic or FISH)
• Acute phase with ≥ 20% bone marrow blasts (M0 to M6 , excluding M3)
• Age ≥ 18 year at inclusion
• PS grade 0 to 2 (ECOG)
• Adequate and organ function, defined as the following: total bilirubin <1.5x uln, sgpt <3x uln, creatinine <1.5x uln.
• Informed consent signed up

Exclusion Criteria:

• active malignancy other than CML or non-melanoma cancer of the skin
• current treatment with another investigational agent
• patients with grade 3/4 cardiac disease or any other serious concurrent medical condition.
• patients who are pregnant or nursing. All patients of childbearing potential must practice effective methods of contraception while on study.
• patients with mental illness or other condition precluding their ability to give informed consent or to comply with study requirements patients with performans status 3-4